Peptide-functionalized nanogels for targeted siRNA delivery.

A major bottleneck in the development of siRNA therapies is their delivery to the desired cell type or tissue, followed by effective passage across the cell membrane with subsequent silencing of the targeted mRNA. To address this problem, we describe the synthesis of core/shell hydrogel nanoparticles (nanogels) with surface-localized peptides that specifically target ovarian carcinoma cell lines possessing high expression levels of the Eph2A receptor. These nanogels are also demonstrated to be highly effective in the noncovalent encapsulation of siRNA and enable cell-specific delivery of the oligonucleotides in serum-containing medium. Cell toxicity and viability assays reveal that the nanogel construct is nontoxic under the conditions studied, as no toxicity or decrease in cell proliferation is observed following delivery. Importantly, a preliminary investigation of gene silencing illustrates that nanogel-mediated delivery of siRNA targeted to the EGF receptor results in knockdown of that receptor. Excellent protection of siRNA during endosomal uptake and endosomal escape of the nanogels is suggested by these results since siRNA activity in the cytosol is required for gene silencing.

[1]  Ingo Berndt,et al.  Mechanics versus thermodynamics: swelling in multiple-temperature-sensitive core-shell microgels. , 2006, Angewandte Chemie.

[2]  D. Bostwick,et al.  Overexpression of the EphA2 tyrosine kinase in prostate cancer , 1999, The Prostate.

[3]  H. Kuwano,et al.  Expression of EphA2 and E-cadherin in colorectal cancer: correlation with cancer metastasis. , 2004, Oncology Report.

[4]  E. Pasquale,et al.  The ephrin-A1 ligand and its receptor, EphA2, are expressed during tumor neovascularization , 2000, Oncogene.

[5]  Robert Langer,et al.  Small-scale systems for in vivo drug delivery , 2003, Nature Biotechnology.

[6]  M. Kinch,et al.  EphA 2 Overexpression Causes Tumorigenesis of Mammary Epithelial Cells 1 , 2001 .

[7]  T. Minko,et al.  Receptor targeted polymers, dendrimers, liposomes: which nanocarrier is the most efficient for tumor-specific treatment and imaging? , 2008, Journal of controlled release : official journal of the Controlled Release Society.

[8]  K. Leong,et al.  Design of Polyphosphoester-DNA Nanoparticles for Non-Viral Gene Delivery. , 2005, Advances in genetics.

[9]  Elena B Pasquale,et al.  An Ephrin Mimetic Peptide That Selectively Targets the EphA2 Receptor* , 2002, The Journal of Biological Chemistry.

[10]  L. Brannon-Peppas,et al.  Rhodamine-loaded poly(lactic-co-glycolic acid) nanoparticles for investigation of in vitro interactions with breast cancer cells , 2009, Journal of materials science. Materials in medicine.

[11]  Robert Langer,et al.  Advancing the field of drug delivery: taking aim at cancer. , 2003, Cancer cell.

[12]  Tae Gwan Park,et al.  Amine-functionalized gold nanoparticles as non-cytotoxic and efficient intracellular siRNA delivery carriers. , 2008, International journal of pharmaceutics.

[13]  A. Sood,et al.  Antivascular Therapy for Orthotopic Human Ovarian Carcinoma through Blockade of the Vascular Endothelial Growth Factor and Epidermal Growth Factor Receptors , 2005, Clinical Cancer Research.

[14]  P. Low,et al.  Delivery of liposomes into cultured KB cells via folate receptor-mediated endocytosis. , 1994, The Journal of biological chemistry.

[15]  T. Zatsepin,et al.  Conjugates of oligonucleotides and analogues with cell penetrating peptides as gene silencing agents. , 2005, Current pharmaceutical design.

[16]  H. Mao,et al.  Self-assembled biodegradable micellar nanoparticles of amphiphilic and cationic block copolymer for siRNA delivery. , 2008, Biomaterials.

[17]  L. Andrew Lyon,et al.  Synthesis and Characterization of Multiresponsive Core−Shell Microgels , 2000 .

[18]  齋藤 徹也.  Expression of EphA2 and E-cadherin in colorectal cancer : correlation with cancer metastasis , 2006 .

[19]  T. Park,et al.  LHRH receptor-mediated delivery of siRNA using polyelectrolyte complex micelles self-assembled from siRNA-PEG-LHRH conjugate and PEI. , 2008, Bioconjugate chemistry.

[20]  Lang Li,et al.  High-level expression of EphA2 receptor tyrosine kinase in prostatic intraepithelial neoplasia. , 2003, The American journal of pathology.

[21]  Tae Gwan Park,et al.  Self-crosslinked and reducible fusogenic peptides for intracellular delivery of siRNA. , 2008, Biopolymers.

[22]  M. Kinch,et al.  EphA2 overexpression causes tumorigenesis of mammary epithelial cells. , 2001, Cancer research.

[23]  J. Nesland,et al.  The clinical significance of EphA2 and Ephrin A-1 in epithelial ovarian carcinomas. , 2005, Gynecologic oncology.

[24]  S. Vinogradov.  Colloidal microgels in drug delivery applications. , 2006, Current pharmaceutical design.

[25]  Qi Zhou,et al.  Materializing the potential of small interfering RNA via a tumor-targeting nanodelivery system. , 2007, Cancer research.

[26]  S. Akhtar,et al.  Nonviral delivery of synthetic siRNAs in vivo. , 2007, The Journal of clinical investigation.

[27]  M. Kanamori,et al.  Correlation of EPHA2 overexpression with high microvessel count in human primary colorectal cancer , 2004, Cancer science.

[28]  Karen L Wooley,et al.  Cationic shell-crosslinked knedel-like nanoparticles for highly efficient gene and oligonucleotide transfection of mammalian cells. , 2009, Biomaterials.

[29]  R. Juliano,et al.  Tat-Conjugated PAMAM Dendrimers as Delivery Agents for Antisense and siRNA Oligonucleotides , 2005, Pharmaceutical Research.

[30]  M. Kinch,et al.  Activation of EphA2 kinase suppresses integrin function and causes focal-adhesion-kinase dephosphorylation , 2000, Nature Cell Biology.

[31]  Ravi Salgia,et al.  The role of ephrins and Eph receptors in cancer. , 2004, Cytokine & growth factor reviews.

[32]  L. Sepp-Lorenzino,et al.  Challenges and Opportunities for Local and Systemic Delivery of siRNA and Antisense Oligonucleotides , 2008, Clinical pharmacology and therapeutics.

[33]  B. Volkman,et al.  Alanine-scanning Mutagenesis of Plasmatocyte Spreading Peptide Identifies Critical Residues for Biological Activity* , 2001, The Journal of Biological Chemistry.

[34]  John F. McDonald,et al.  Magnetic nanoparticle-peptide conjugates for in vitro and in vivo targeting and extraction of cancer cells. , 2008, Journal of the American Chemical Society.

[35]  G. Roth,et al.  Small Molecules Can Selectively Inhibit Ephrin Binding to the EphA4 and EphA2 Receptors* , 2008, Journal of Biological Chemistry.

[36]  Henning Urlaub,et al.  Single-Stranded Antisense siRNAs Guide Target RNA Cleavage in RNAi , 2002, Cell.

[37]  R. Bellamkonda,et al.  Targeted drug delivery to C6 glioma by transferrin-coupled liposomes. , 2000, Journal of biomedical materials research.

[38]  H. Maeda.  The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. , 2001, Advances in enzyme regulation.

[39]  Z. Hall.  Cancer , 1906, The Hospital.

[40]  A. Sood,et al.  EphA2 Expression Is Associated with Aggressive Features in Ovarian Carcinoma , 2004, Clinical Cancer Research.

[41]  Liz Y. Han,et al.  EphA2 overexpression is associated with angiogenesis in ovarian cancer , 2007, Cancer.

[42]  Andrew D. Miller,et al.  Lipidic carriers of siRNA: differences in the formulation, cellular uptake, and delivery with plasmid DNA. , 2004, Biochemistry.

[43]  E. Kumacheva,et al.  Biofunctionalized pH‐Responsive Microgels for Cancer Cell Targeting: Rational Design , 2006 .

[44]  W. H. Blackburn,et al.  Size-controlled synthesis of monodisperse core/shell nanogels , 2008, Colloid and polymer science.

[45]  Yu-Kyoung Oh,et al.  siRNA conjugate delivery systems. , 2009, Bioconjugate chemistry.

[46]  M. Morris,et al.  Insight into the mechanism of the peptide-based gene delivery system MPG: implications for delivery of siRNA into mammalian cells. , 2003, Nucleic acids research.

[47]  V. Torchilin,et al.  siRNA-containing liposomes modified with polyarginine effectively silence the targeted gene , 2006, Journal of Controlled Release.

[48]  Dana M. Brantley-Sieders,et al.  Impaired tumor microenvironment in EphA2‐deficient mice inhibits tumor angiogenesis and metastatic progression , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[49]  R. Williford,et al.  Hybrid nanogels for sustainable positive thermosensitive drug release. , 2001, Journal of controlled release : official journal of the Controlled Release Society.

[50]  B. Deurs,et al.  Activation of the EGFR Gene Target EphA2 Inhibits Epidermal Growth Factor–Induced Cancer Cell Motility , 2007, Molecular Cancer Research.

[51]  Cornelus F. van Nostrum,et al.  Polymeric micelles to deliver photosensitizers for photodynamic therapy. , 2004 .

[52]  Erkki Ruoslahti,et al.  Targeted quantum dot conjugates for siRNA delivery. , 2007, Bioconjugate chemistry.

[53]  R. Schiffelers,et al.  Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle. , 2004, Nucleic acids research.

[54]  R. Juliano.  Peptide-oligonucleotide conjugates for the delivery of antisense and siRNA. , 2005, Current opinion in molecular therapeutics.

[55]  Robert Langer,et al.  Formulation of functionalized PLGA-PEG nanoparticles for in vivo targeted drug delivery. , 2007, Biomaterials.

[56]  Jean Chmielewski,et al.  Folate-mediated cell targeting and cytotoxicity using thermoresponsive microgels. , 2004, Journal of the American Chemical Society.

[57]  Judy Lieberman,et al.  Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors , 2005, Nature Biotechnology.